Medikal Tedaviye Yan？ts？z Duktus Arteriosuslu Preterm ？nfantlar？n Tedavisinde Güvenli Bir Y？ntem: Yatakba？？ Cerrahi ligasyon

The appropriate management of patent ductus arteriosus (PDA) and associated complications (such as congestive heart failure, bronchopulmonary dysplasia, necrotizing enterocolitis, intracranial hemorrhage and death), which is one of these morbidities, is very important for the improvement of short and long-term results. Aim The aim of this study was to retrospectively evaluate the results of premature infants who underwent bedside surgery PDA ligation after a non-responding medical closure therapy. Methods In this retrospective study, the results of babies who underwent bedside surgical PDA ligation with the diagnosis of HAPDA in the neonatal intensive care unit (NICU) were evaluated retrospectively. 84 premature babies were included in the study. Demographic characteristics, type and duration of pre- and postoperative respiratory support, intraventricular hemorrhage and bronchopulmonary dysplasia rates, hospital stay duration and mortality data were analyzed. Results 84 premature infants were included in the study. In 61 infants (72.6%) closure with medical treatment and surgical ligation in 23 infants (27.4%) were performed with the diagnosis of HAPDA. The median operating age was 35 (25-46) days and the median body weight on the day of surgery was 1150 g (870-1100 g). In the group undergoing surgical ligation, a baby (4.3%) was lost about 60 days after the administration, while 22 infants could be discharged. Respiratory support, oxygen withdrawal and discharge time of the babies who needed ligation were statistically significantly longer than those responding to medical treatment (p <0.001). No complication related to surgery was observed in infants who underwent bed ligand surgery. Conclusions The prolonged patency of the ductus arteriosus in preterm infants is related to an increased morbidity. Bedside PDA ligation in NICUs where there is no pediatric cardiovascular surgery team should be kept in mind as an alternative safe method to reduce PDA-related morbidity and mortality by preventing delay in treatment in patients who do not respond to medical treatment